Enlarged Prostate (BPH)
Also known as: Benign prostatic hyperplasia
Methodology & AI Transparency ⓘ
Enlarged Prostate (BPH) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is the prostate? The prostate is a gland in the male reproductive system.
- 2 Real-world patient consensus: Synonyms for Enlarged Prostate (BPH) (N39.6): Benign prostatic hyperplasia (Urology & Prostate).
- 3 Typical cash cost range: Clinicians assessing Enlarged Prostate (BPH) focus on prostatic fibromuscular stromal in Enlarged Prostate (BPH) (N39.6: hyperplasia) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Enlarged Prostate (BPH) monitoring tracks IPSS Urinary Symptom in Enlarged Prostate (BPH) (N39.6: Score) toward 0 – 7 (mild symptoms) (N39.6).
Ask our AI Specialists anything about Enlarged Prostate (BPH)
What Is Enlarged Prostate (BPH)?
What is the prostate? The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. What is an enlarged prostate (BPH)? An enlarged prostate is when your prostate gland becomes larger than normal. It's also called benign prostatic hyperplasia or BPH for short. Benign means not cancer. And hyperplasia means too much cell growth. BPH isn't cancer and it doesn't increase your risk of getting prostate cancer . Usually, the prostate gland continues to grow during adult life. That's why BPH is the most common prostate condition in people over age 50.
Pathophysiology, Underlying Causes & Clinical Presentation
In Enlarged Prostate (BPH) (N39.6), physiological disruption stems from prostatic fibromuscular stromal in Enlarged Prostate (BPH) (N39.6: hyperplasia), Cross-referenced with NIH MeSH (Prostatic Hyperplasia), informing Prostate (BPH), Bladder & Urinary Tract protocols that track Urinalysis & Post-Void in Enlarged Prostate (BPH) (N39.6: Residual (PVR)) (Negative leukocyte/nitrite; PVR < 50 mL (N39.6)).
Common Symptoms & Clinical Signs
- • Are age 40 or older. The chance of getting BPH increases as you get older
- • Have family members who have had BPH
- • Presentation of Enlarged Prostate (BPH) (N39.6): weak, hesitant, or in Enlarged Prostate (BPH) (N39.6: intermittent urinary stream)
- • Secondary Enlarged Prostate (BPH) clinical sign: waking two or in Enlarged Prostate (BPH) (N39.6: more times nightly)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Enlarged Prostate (BPH) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N39.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Enlarged Prostate (BPH) (N39.6: Score) | 0 – 7 (mild symptoms) (N39.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Enlarged Prostate (BPH) (N39.6: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N39.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Enlarged Prostate (BPH) (N39.6: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N39.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Enlarged Prostate (BPH)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Apalutamide Erleada • RxCUI 1999581 | FDA Prescription Therapeutic Agent | 89% | $0.2200 | $ 17.41 /mo |
| Choline C-11 Choline C-11 Generic • RxCUI RXN-52670556-1744 | Radioactive Diagnostic Agent | 76% | $2.1000 | $ 93.55 /mo |
| Kit for The Preparation of Gallium Ga 68 Gozetotide Locametz • RxCUI RXN-00781224-1779 | FDA Prescription Therapeutic Agent | 87% | $2.6700 | $ 116.64 /mo |
| Radium Ra 223 Dichloride Xofigo • RxCUI 1424214 | Radioactive alpha-Particle Emitting Therapeutic Agent | 87% | $2.3400 | $ 103.27 /mo |
| Fluciclovine F-18 Axumin • RxCUI RXN-69932001-1754 | Radioactive Diagnostic Agent | 93% | $1.7100 | $ 77.75 /mo |
| Nilutamide Nilutamide Generic • RxCUI 311982 | Androgen Receptor Inhibitor | 86% | $3.0700 | $ 132.83 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Enlarged Prostate (BPH))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on [Therapeutic effect of tadalafil on lower urinary tract symptoms with erectile Daily administration of tadalafil at 5 mg can effectively improve the IPSS sub-item scores in the urinary storage symptoms and IIEF-5 scores, with a persistent effect after withdrawal similar to that of its combination with... Zhonghua nan ke xue = National journal of andrology • 2019-06-15 • Randomized Controlled Trial | N = 126 | 88/100 | PMID 32223086 ↗ |
| Can This Approach Help? Inside the Latest Research on Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Moreover, the disease control rate (complete full symptom relief/partial full symptom relief/stable disease) of the primary disease was seen in 59.1%, 70.6%, and 87.0% of patients with an enlarged pore score of 1, 2, and 3,... The Journal of dermatology • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40503645 ↗ |
Enlarged Prostate (BPH) Patient Community & “People Like Me” Threads
Filter Enlarged Prostate (BPH) community threads and patient logs by age, biological sex, dosage, and treatment duration.